BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Varthaman A, Lacroix-Desmazes S. Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance? Haematologica 2019;104:236-44. [PMID: 30514798 DOI: 10.3324/haematol.2018.206383] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 de Oliveira LMM, Jardim LL, Santana MAP, Cerqueira MH, Lorenzato CS, Franco VKB, Zuccherato LW, Rezende SM, Chaves DG. Effect of the First Factor VIII Infusions on Immunological Biomarkers in Previously Untreated Patients with Hemophilia A from the HEMFIL Study. Thromb Haemost 2021;121:891-9. [PMID: 33423244 DOI: 10.1055/s-0040-1722353] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Cormier M, Batty P, Tarrant J, Lillicrap D. Advances in knowledge of inhibitor formation in severe haemophilia A. Br J Haematol 2020;189:39-53. [DOI: 10.1111/bjh.16377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
3 Matino D, Afraz S, Zhao G, Tieu P, Gargaro M, Fallarino F, Iorio A. Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dyoxigenase-1 and Heme Oxygenase-1. Front Immunol 2020;11:620. [PMID: 32351505 DOI: 10.3389/fimmu.2020.00620] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Mimoun A, Delignat S, Peyron I, Daventure V, Lecerf M, Dimitrov JD, Kaveri SV, Bayry J, Lacroix-Desmazes S. Relevance of the Materno-Fetal Interface for the Induction of Antigen-Specific Immune Tolerance. Front Immunol 2020;11:810. [PMID: 32477339 DOI: 10.3389/fimmu.2020.00810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Lacroix-Desmazes S, Voorberg J, Lillicrap D, Scott DW, Pratt KP. Tolerating Factor VIII: Recent Progress. Front Immunol 2019;10:2991. [PMID: 31998296 DOI: 10.3389/fimmu.2019.02991] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
6 Schep SJ, Schutgens REG, Fischer K, Voorberg J, Boes M. Role of Regulatory Cells in Immune Tolerance Induction in Hemophilia A. Hemasphere 2021;5:e557. [PMID: 33898928 DOI: 10.1097/HS9.0000000000000557] [Reference Citation Analysis]
7 Delignat S, Rayes J, Dasgupta S, Gangadharan B, Denis CV, Christophe OD, Bayry J, Kaveri SV, Lacroix-Desmazes S. Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells. Front Immunol 2020;11:393. [PMID: 32273875 DOI: 10.3389/fimmu.2020.00393] [Reference Citation Analysis]
8 Schurgers E, Wraith DC. Induction of Tolerance to Therapeutic Proteins With Antigen-Processing Independent T Cell Epitopes: Controlling Immune Responses to Biologics. Front Immunol 2021;12:742695. [PMID: 34567009 DOI: 10.3389/fimmu.2021.742695] [Reference Citation Analysis]
9 Khalilian S, Motovali-Bashi M, Rezaie H. Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients. Int J Mol Cell Med 2020;9:33-50. [PMID: 32832483 DOI: 10.22088/IJMCM.BUMS.9.1.33] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Coxon CH, Yu X, Beavis J, Diaz-Saez L, Riches-Duit A, Ball C, Diamond SL, Raut S. Characterisation and application of recombinant FVIII-neutralising antibodies from haemophilia A inhibitor patients. Br J Haematol 2021;193:976-87. [PMID: 33973229 DOI: 10.1111/bjh.17227] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 O’connor DJ, Buckland J, Almond N, Boyle J, Coxon C, Gaki E, Martin J, Mattiuzzo G, Metcalfe C, Page M, Rose N, Valdazo-gonzalez B, Zhao Y, Schneider CK. Commonly setting biological standards in rare diseases. Expert Opinion on Orphan Drugs 2019;7:305-14. [DOI: 10.1080/21678707.2019.1652598] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Schep SJ, Boes M, Schutgens RE, van Vulpen LF. An update on the ‘danger theory’ in inhibitor development in hemophilia A. Expert Review of Hematology 2019;12:335-44. [DOI: 10.1080/17474086.2019.1604213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
13 Thachil J. Potential Clues to the Pathogenesis of Acquired Hemophilia. Semin Thromb Hemost 2021. [PMID: 33647996 DOI: 10.1055/s-0040-1722294] [Reference Citation Analysis]
14 Camelo RM, Chaves DG, Zuccherato LW, Rezende SM; BrazIT Study Team. Predictors of the outcome of immune tolerance induction in patients with haemophilia A and inhibitors: The Brazilian Immune Tolerance (BrazIT) Study protocol. PLoS One 2021;16:e0256265. [PMID: 34437573 DOI: 10.1371/journal.pone.0256265] [Reference Citation Analysis]